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INTRODUCTION
Group B streptococcus (GBS, also known as Streptococcus
agalactiae) was first described as a pathogenic organism of
the human body 60 yr ago (1), and was identified as the most
frequent cause of neonatal sepsis and meningitis in the 1970s
(2). Since then, GBS has emerged as a major pathogen for a
variety of bacterial infections among pregnant women, non-
pregnant adults, and the aged (3). In the United States, screen-
ing followed by intrapartum antibiotics has halved the rate
of early-onset neonatal sepsis (4), but GBS remains the most
common cause of early onset neonatal sepsis, and the inci-
dence of late-onset neonatal disease and other GBS infections
in pregnancy has remained unchanged. Further, the emer-
gence of GBS resistant to second-line treatments used for
those allergic to penicillin has complicated treatment deci-
sions. Thus, a prenatal screening program followed by antibi-
otic treatment is only an interim solution; studies to devel-
op an effective vaccine based on the capsular polysaccharide
(CPS), which determines serotype, are ongoing (5). There are
9 (and possibly 10) known serotypes (6); the distribution of
serotypes differs by geographic area. 
Despite its importance as a pathogen, there are few stud-
ies of GBS in Asia generally, and Korea in particular. As has
been true elsewhere, the role of GBS as a neonatal pathogen
was previously overlooked in Korea; only recently did inves-
tigations identify GBS as the most common cause of neona-
tal bacterial meningitis (7). GBS prevalence among those
pregnant women screened in Korea is about 5% (8), lower
than that of Germany (16%) (9) or the United States (20%)
(10). However, macrolide resistance among isolates tested has
increased in the previous 10 yr (9). Moreover the prevalence
of GBS in pregnant women has increased to 8% in Korea
(11). Thus, there is much to be learned about the epidemi-
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Changing Molecular Epidemiology of Group B Streptococcus in Korea
The prevalence of group B streptococcus (GBS) among pregnant women and dis-
ease burdens in neonates and adults are increasing in Korea. Colonizing isolates,
collected by screening pregnant women (n=196), and clinical isolates collected from
clinical patients throughout Korea (n=234), were serotyped and screened for antibi-
otic resistance. Serotype III (29.8%) and V (27.7%) predominated, followed by Ia
(17.0%). Antibiotic resistance was higher among clinical than colonizing isolates for
erythromycin (35.1% and 26.9%; P=0.10) and for clindamycin (49.4% and 42.1%;
P=0.17). erm(B) occurred in 91.9% of erythromycin resistant isolates, and 84.0%
of isolates resistant to clindamycin. Only five isolates (4.2%) resistant to erythromycin
were susceptible to clindamycin; by contrast, and unique to Korea, 34% of isolates
resistant to clindamycin were erythromycin susceptible. Among these 60 erythro-
mycin-susceptible & clindamycin-resistant isolates, 88% was serotype III, and lnu(B)
was found in 89% of strains. Four fifths of the serotype V isolates were resistant to
both erythromycin and clindamycin. Further characterization of the genetic assem-
bly of these resistance conferring genes, erm(B) and lnu(B), will be useful to estab-
lish the clonal lineages of multiple resistance genes carrying strains.
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to treat and prevent GBS disease in Korea, but because of
the potential for spread of resistant strains throughout the
world. In this study, we investigated the serotype character-
istics, antibiotic phenotype and genotype (erm[A], erm[B],
mef[A] and lnu[B]), among GBS isolates collected from preg-
nant women and clinical patients from year 2004 to 2007
in Korea. 
MATERIALS AND METHODS
Study collection 
The study collection included 196 colonizing isolates col-
lected from 140 asymptomatic pregnant women (35-37 weeks
of gestation) and 234 clinical isolates collected from 231 pa-
tients with GBS infection. GBS isolates were collected from
pregnant women receiving prenatal care at four hospitals,
Eulji Hospitals in Seoul and Daejeon, Cheil Hospital in Seoul,
and Motae Women’s Hospital in Daejeon.
The isolates from clinical patients were sent to the Seoul
Clinical Laboratories & Seoul Medical Science Institute (SCL)
for microorganism culture from hospitals and clinics through-
out the country between January, 2006 and March, 2007
(Table 1). 
Written informed consent was obtained from all pregnant
women, and the study protocol was approved by the Insti-
tutional Review Board of Eulji University Hospital (04-08
and 06-25), and Cheil Hospital (SCH-IRB-2005-24).
Sample collection and isolation of GBS
Mucus or discharge were collected on a swab from the vagi-
nal mucosa (vagina introitus) of pregnant women without
using a speculum and then placed in Stuart transport medi-
um. A rectal swab was rolled two to three times around the
rectal opening, and placed in a separate Stuart transport medi-
um. About 20 mL of initial urine of pregnant women were
collected in a sterile urine cup. The following protocol was
used for specimen culture and bacteria identification in each
laboratory and SCL. All media and supplies were purchased
by the research team and distributed to participating labora-
tories. All isolates were cultured by using a selective media
(Todd-Hewitt [TH]broth supplemented with either gentam-
icin [8 mg/mL] and nalidixic acid [15 mg/mL], or with colistin
[10 mg/mL] and nalidixic acid [15 mg/mL]) to prevent growth
of bacteria other than GBS. Urine was centrifuged and 1 mL
of the bottom part was put in the selective media. Swabs of
vaginal and rectal specimen were transferred directly from
transport to selective media, and shaken three or four times
so that the specimens were thoroughly mixed with the selec-
tive medium. The cap of the selective media was loosely clos-
ed and cultured in a 5% CO2 incubator at 35-37℃ for 18-
24 hr; a negative control of selective media was cultured with
each group of swabs. Tubes were checked for GBS growth
after 18-24 hr, and then again after 48 hr. If bacterial growth
was observed in the selective media, the bacteria were cultured
on a sheep blood agar plate, that is, a tryptic soy agar with
5% defibrinated sheep blood (TSAII; KOMED Co., Sung-
nam, Korea). We used a catalase test followed by a latex agglu-
tination assay (Streptex; Murex Biotech Ltd., Dartford, Eng-
land) to confirm the isolate was GBS. All confirmed GBS
isolates were tested for sensitivity to penicillin G, ampicillin,
erythromycin, clindamycin, cefazolin (or cefuroxime) and
vancomycin by using microtiter broth determinations. Ery-
thromycin-resistant, clindamycin-susceptible isolates are
tested for inducible clindamycin resistance by double-disk
diffusion (D test). Interpretation is based on the protocols of
Clinical and Laboratory Standards Institute (CLSI, formerly
NCCLS) (12).
Serotyping of GBS isolates
GBS-kit, Essum
� products of Sweden was used for deter-
mining serotypes. Dot blot capsular type (13) in a microar-
ray format (14) was performed for isolates that were catego-
rized as non-typeable by this test (54 cases, 12.6% of the total),
by using protocols described previously and serotypes were
determined for all 430 GBS strains. The following isolates
were used as positive controls for dot blot capsular typing:
CNCTC 1/85 (Ia), DK14 (Ib), DK23 (II), M781 (III), CNCTC
1/82 (IV), CNCTC 10/84 (V), NT6 (VI), 87-603 (VII), and
JM9 (VIII) (C.E. Rubens collection) (15). 
Detection of resistance genes with Library on slide
hybridization 
GBS strains were inoculated in 9 mL of TH broth (BD,
Sparks, MD, USA) and then incubated at 37℃with 5% CO2
for 18-24 hr. Genomic DNA was extracted and purified by
using sonication and heat treatment as previously described
(14). The genomic DNA from 408 of the 430 strains (95%)
were arrayed in duplicate on Vivid Gene Array slides with
nylon membranes (Pall, Ann Arbor, MI, USA) by using the
VersArray ChipWriter Compact system (Bio-Rad, Hercules,
CA, USA). 22 of the isolates from the original collection were
not included in the library on a slide because of low cell den-
sity during DNA extraction procedures, despite repeated
attempts to culture. 
Polymerase chain reaction (PCR) amplification of probe
sequences was performed by the following method: DNA
lysates were prepared from 3 mL of GBS overnight culture
in TH broth. Each reaction mixture (48 mL) included 50
pmole of each primer, 1 mL of diluted DNA lysate, and 45
mL of Accuprime super mix II (Invitrogen, San Diego, CA,
USA). Primers to detect erm(B) and mef(A) and lnu(B) were
described previously (8). Primers were designed to amplify
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sequence 5′ -AAA ATA ATA GAA ATT GGG TCA GGA
AAA GGA CAT TTT ACC-3′ and 5′ -CCC ATT TAT AAA
CGA AAA ATC TAT ACT TTT TGT AGT CCT TCT T-
3′ . Reactions were carried out by using a Bio-Rad MyCy-
clerTM by using the following conditions: denaturation at
94℃for 30 sec, annealing at 54℃(erm[A], erm[B]and lnu[B])
or 57℃ for 30 sec (mef[A]) for 35 cycles, and elongation at
68℃ for 1 min, followed by a final elongation at 68℃ for
6 min. A total of 10 mL of PCR product was analyzed by elec-
trophoresis on a 1% agarose gel, stained with 0.02 mg/mL of
ethidium bromide, and visualized by UV transillumination.
PCR amplification products were purified by using the
QIAquick gel extraction kit and the QIAquick PCR purifi-
cation kit (QIAGEN Inc., Valencia, CA, USA) and labeled
with 2.5 mL of 1 mM/L fluorescein-12-dCTP (PerkinElmer,
Boston, MA, USA) by using a modification of the BioPrime
DNA Labeling System (Invitrogen) as previously described
(16). The quantification probe (labeled with digoxigenin)
consisted of a mixture of GBS housekeeping genes (adh[P],
glc[K], gln[A], and phe[S]) was used to account for differences
in genomic DNA concentrations across strains. The probes
were hybridized in duplicate to genomic DNA arrayed on
slides by using previously described methods; hybridization
signals were detected by using an Arrayit ChipReader and
analyzed with IconoClust software (16). The signal intensity
of the spots were adjusted for background and normalized
to the signal intensity of a quantification probe. Cutoffs for
probe positive strains were established by using previously
published methods (17). PCR was used to confirm presence
or absence of antimicrobial resistance genes for strains where
hybridization results were inconclusive. 
We compared the frequency of serotype and antimicrobial
resistance between colonized and clinical GBS strains by using
the chi-square test. 
RESULTS
Study isolates (n=430) were collected over a 3 yr period
from various geographic areas in Korea (Table 1). All coloniz-
ing isolates were from pregnancy screening, whereas clinical
isolates were from ‘test requested’ samples to the Seoul Clin-
ical Laboratory from throughout Korea. The clinical isolates
were from urine (50.4%), surgical wound (10.3%), pus or
abscess (8.1%), vagina (7.7%), cervix (6.0%), blood or cere-
brospinal fluid (3.9%), prostate (3.0%), sputum (1.7%), and
others (9.0%). The colonizing isolates were from the urine
(42.9%), vagina (27.0%), rectum (21.9%) or from combined
vaginal/rectal specimens (8.2%). In several cases multiple iso-
lates were collected from different sites in a single individu-
al; we assumed these isolates were the same if the isolates had
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*Isolated from clinical patients.
GBS collection Characteristic 
(n=430)
Age range
(yr)
Culture date Isolation source
Pregnant women presenting at the  Vagino-rectal Nov. 2004 to Dec. 2005 23-42 Colonized (16)
Eulji Hospital in Seoul or Daejeon  Urine, vagina, rectum Nov. 2006 to June. 2007 Colonized (15)
for prenatal care
Pregnant women presenting at the  Urine, vagina, rectum Jan. 2006 to Mar. 2007 21-45 Colonized (165)
Cheil Hospital in Seoul or Motae Hospital 
in Daejeon for prenatal care
Test requested samples to Seoul Clinical  Surgical wound, blood,  Jan. 2006 to Mar. 2007 1-92 Clinical (234)
Laboratories (SCL) from the whole country* urine, vagina, etc.
Table 1. Characteristics of group B streptococcus (GBS) collections
Pregnant women
(colonizing) All isolates 
(430)
Unique
isolates (376)
Redundancy
(54)
Low DNA 
concentration (22)
Genotyped
isolates (354)
196 234
145
51 3
10 12
231
135 219
Clinical patients
(clinical)
Fig. 1. Schematic diagram for study isolates
collected from Korea (2004 to 2007).the same serotype, antibiotic resistance profile and antibiot-
ic resistance genotype (erm[A], erm[B], mef[A] and lnu[B]). Six
individuals had two different isolates; the remaining analy-
ses are limited to the 376 unique isolates obtained from 371
individuals. Genotype for erythromycin and clindamycin resis-
tance was generated for 354 isolates, because of low DNA
concentration (Fig. 1).
Overall, serotype III (29.8%) and V (27.7%) predominat-
ed, followed by Ia (17.0%, Table 2). Serotype III (35.2%) pre-
dominated than serotype V (24.1%) among colonizing iso-
lates, whereas serotype V (29.9%) was predominant, followed
serotype III (26.4%) among clinical isolates, but the serotype
distribution did not differ significantly between colonizing
and clinical isolates (P=0.18, Table 3). 
The frequency of erythromycin and clindamycin resistance
was higher among clinical than colonizing isolates: 26.9%
of colonizing isolates and 35.1% of clinical isolates showed
resistance to erythromycin (P=0.10), while 42.1% of coloniz-
ing, and 49.4% of the clinical isolates were resistant to clin-
damycin (P=0.17). The resistance rates to both erythromycin
and clindamycin were 24.8% of colonizing and 34.2% of clin-
ical isolates, and the differences showed borderline significance
(P=0.06). Combining colonizing and clinical isolates, the over-
all resistance to erythromycin was 31.9% and to clindamycin
was 46.5%. All but four isolates resistant to erythromycin
were also resistant to clindamycin, but 34.3% (60/175) of
those resistant to clindamycin were susceptible (or showed
intermediate) to erythromycin. No isolates were resistant to
ampicillin, penicillin G, or vancomycin. One isolate (0.7%)
showed intermediate to cefazolin, a first generation cephalo-
sporin used to test for resistance among colonizing isolates.
Clinical isolates were tested for resistance to cefuroxime sodi-
um, a second generation cephalosporin; three isolates (1.3%)
were resistant (Fig. 2).
Most erythromycin and clindamycin resistance occurred
in serotypes III and V. Serotypes VII and VIII also had high
levels of resistance, but the numbers in these groups are small.
Serotype III strains were more resistant to clindamycin (61.6%)
than to erythromycin (16.1%), with 47.3% of isolates resis-
tant to clindamycin only and 1.8% resistant to erythromycin
820 Y.S. Seo, U. Srinivasan, K.-Y. Oh, et al.
*Intermediate were included in susceptible group; 
� Three isolates resistant to erythromycin demonstrated inducible clindamycin resistance on a dou-
ble disc diffusion test are not included.
Serotype
No. (%)
Susceptible* to 
erythromycin and 
clindamycin
No. (%)
Resistance to 
erythromycin and 
clindamycin
No. (%)
Resistance to 
clindamycin only
�
No. (%)
Resistance to 
erythromycin only
No. (%)
Ia 64 (17.0) 60 (93.8) 1 (1.6) 2 (3.1) 1 (1.6)
Ib 35 (9.3) 29 (82.9) 0 (-) 5 (14.3) 1 (2.9)
II 19 (5.1) 19 (100.0) 0 (-)0  ( -)0  ( -)
III 112 (29.8) 41 (36.6) 16 (14.3) 53 (47.3) 2 (1.8)
V 104 (27.7) 19 (18.3) 84 (80.8) 0 (-) 1 (1.0)
VI 26 (6.9) 22 (84.6) 4 (15.4) 0 (-)0  ( -)
VII 3 (0.8) 0 (-) 3 (100.0) 0 (-)0  ( -)
VIII 11 (2.9) 4 (36.4) 7 (63.6) 0 (-)0  ( -)
Variable type 2 (0.5) 2 (100.0) 0 (-)0  ( -)0  ( -)
Total 376 (100.0) 196 (52.1) 115 (30.6) 60 (16.0) 5 (1.3)
Table 2. Frequency of erythromycin and clindamycin resistance by serotype of group B streptococcus isolates collected from Korea
(2004 to 2007)
*Non-typeable. 
Year
Ia Ib II III IV V VI VII VIII NT*
GBS serotypes (%)
Reference
No. of 
isolates
1979-1992 109 14.7 35.8 10.1 33.0 0.0 1.8 0.0 0.0 0.0 4.6 Lee et al. 
(2000)
1993-1996 200 11.5 39.5 1.0 37.5 1.0 3.5 3.0 0.0 2.0 1.0
1997-2002 350 10.0 16.3 1.1 36.0 1.4 26.0 5.4 0.9 1.4 1.4 Uh et al. 
(2005)
2004-2007 145 17.9 11.0 5.5 35.2 0.0 24.1 2.8 0.7 2.8 0.0 This study 
(colonizing)
2006-2007 231 16.5 8.2 4.8 26.4 0.0 29.9 9.5 0.9 3.0 0.9 (clinical)
Table 3. Summary of group B streptococcus (GBS) serotype distributions in Koreaonly (Table 2). Resistance was mainly constitutive; out of four
strains that were phenotypically erythromycin resistant and
clindamycin susceptible, erythromycin induced clindamycin
resistance was seen in three; one strain was erm(A) positive
and two strains were erm(B) positive.
Among the 376 unique isolates, 354 isolates were screened
for the presence of resistance genes (Table 4). The most preva-
lent gene was erm(B) (46.6%, 165/354) and lnu(B) was detect-
ed in 19.8% (70/354) of strains. erm(A) (2.0%, 7/354) and
mef(A) (2.3%, 8/354) occurred in less than 3% of isolates.
Most erythromycin resistant isolates (91.9%, 102/111) and
clindamycin resistant isolates (84.0%, 136/162) were erm(B)
positive, while 14.4% (27/188) of both erythromycin and
clindamycin susceptible isolates were erm(B) positive. lnu(B)
was detected in 89.0% (49/55) in the isolates resistant to only
clindamycin. mef(A) was not found in any of the isolates sus-
ceptible to both erythromycin and clindamycin. In all but
one case, mef(A) occurred with erm(B) and lnu(B). lnu(B) was
also highly associated with erm(B) (77.1%, 54/70 strains).
DISCUSSION
Among 430 isolates (376 unique isolates) from Korea col-
lected between 2004-2007, we observed changing serotype
distributions and high rates of resistance to erythromycin
and clindamycin, with resistance levels varying by serotype.
Clindamycin resistance is explained by presence of the lin-
cosamide nucleotidyltransferase lnu(B), which inactivates lin-
cosamides and clindamycin and confers resistance to clin-
damycin. 
The distributions of serotypes observed in Korea has chang-
ed by years; Ib and III were dominant from 1979 to 1996
(18), and III was predominant and V was the next from 1997
to 2002 (19). However, in this study serotype V was predom-
inant among clinical isolates (Table 3). The differences in
serotype distribution among various populations may reflect
differences in pathogenesis among the serotypes. Therefore,
monitoring the serotype distribution is important for com-
plete surveillance of GBS infections and for vaccine formu-
lation. 
Our study showed increased antibiotic resistance rate to
clindamycin (35% (19) vs. 46.5%) and identified resistance
to cefazolin and cefuroxime. Antibiotic resistance occurred
almost exclusively among serotypes III and V; this is consis-
tent with reports from elsewhere (4). Unlike reports from the
United States, Canada, or Germany, resistance to clindamycin
exceeded that for erythromycin (8, 20, 21). The ‘‘separation
in prescribing and dispensing of medications’’ policy in Korea
practiced since in August 2000 was expected to decrease
antibiotic prescription and reduce the selection pressure for
resistance. It is possible that problems implementing this
health care policy (22) have limited the potential benefits or
that the bacteria have developed compensatory mechanisms
so that reversion to antibiotic sensitivity is less likely, or both.
There are two primary mechanisms known to cause ery-
thromycin resistance in GBS: target site modification and
active efflux (23, 24). Target site modification is mediated by
erythromycin resistance methylase, which is encoded by the
erm class genes. Macrolide efflux, which is caused by a mem-
brane protein encoded by the mef class genes, has recently
emerged among S. pyogenes and S. pneumoniae in many coun-
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*Intermediate were included in susceptible group. 
Genotype 
(No.)
Susceptible*
to erythro-
mycin and
clindamycin 
No. (%)
Resistance 
to erythro-
mycin and
clindamycin  
No. (%)
Resistance 
to clinda-
mycin only   
No. (%)
Resistance 
to erythro-
mycin only 
No. (%)
No resistance  157 (83.5) 6 (5.6) 5 (9.1) 0
gene (168)
erm(B) (110) 23 (12.2) 85 (79.4) 1 (1.8) 1 (25.0)
lnu(B) (16) 1 (0.5) 1 (0.9) 14 (25.5) 0
erm(A) (4) 3 (1.6) 0 0 1 (25.0)
mef(A) (1) 0 0 0 1 (25.0)
erm(B) and 4 (2.1) 7 (6.5) 34 (61.8) 0
lnu(B) (45)
erm(B) and  0 1 (0.9) 0 0
erm(A) (1)
erm(B), lnu(B) 0 6  (5.6) 0 1  (25.0)
and mef(A) (7)
erm(B), erm(A)  0 1 (0.9) 1 (1.8) 0
and lnu(B) (2)
Total (354) 188 (100) 107 (100) 55 (100) 4 (100)
Table 4. Resistance genes found among group B streptococ-
cus isolates susceptible and resistant to erythromycin and clin-
damycin
Fig. 2. Frequency of antibiotic resistance among group B strepto-
coccus isolates (n=376) collected from Korea (2004 to 2007). 
*P=0.17, 
� P=0.10, 
� P=0.06. P values were obtained by chi-square
test. All isolates were susceptible to ampicillin, penicillin G, and
vancomycin.
%
60
50
40
30
20
10
0
Cefazoline of Clindamycin* Erythromycin
� Erythromycin 
cefuroxime and
clindamycin
�
42.1
49.4
0 1.3
26.9
35.1
Colonizing (145)
24.8
34.2
Clinical (231)tries (24, 25). We observed very few isolates with mef genes,
or erm genes other than erm(B). Four isolates were genotyped
among five isolates which were resistant to erythromycin and
susceptible to clindamycin (M phenotype); one was mef(A)
positive, another was erm(A) positive, the third was erm(B)
positive, and the other was erm(B), lnu(B) and mef(A) positive.
The M phenotype occurred much less frequently (4.2%; 5/
120) than in Canada (12.1%) (26) or Taiwan (13.7%) (27).
While erm genes are also associated with inducible clindamy-
cin resistance (along with erythromycin resistance), clinda-
mycin resistance alone can also be conferred by lnu(B) which
confers resistance via drug modification (28). lnu(B) was first
described in Enterococcus faecium (28) and found in GBS by
Azavedo et al. in 2001(26). The presence of lnu(B) in our col-
lection (19.8%) likely explains resistance to clindamycin in
the absence of erm genes. The high association of lnu(B) and
erm(B) genes suggest that these genes are linked either physi-
cally or functionally in circulating GBS strains in Korea. The
erm(B) gene is located on the Tn3872 transposon (Tn916 like)
in GBS, it is not known if the lnu(B) gene in GBS is also locat-
ed on a similar transposon or other mobile genetic elements
(29). Interestingly all the erm(B) positive and lnu(B) positive
strains belonged to serotype III. Further characterization of
the genetic assembly of these resistance conferring genes and
the genetic backbone of the strains carrying these genes will
be useful to establish the clonal lineages of multiple resistance
genes carrying strains. 
Although there is substantial selection pressure for GBS
to become resistant to penicillin and macrolides among coun-
tries screening and treating for GBS during pregnancy, GBS
screening during pregnancy is not yet standard of care in
Korea. Because it is a common inhabitant of the human micro-
biota, it is exposed to antibiotics taken by its human host
for any reason, and can exchange genes with other microbes
in the microbiota. 
In conclusion, the molecular epidemiology of GBS in Korea
is changing; the proportion of serotype Ib has decreased, sero-
type V has increased, and sertoypes VI, and VIII are emerg-
ing especially among clinical isolates. Four fifths of the sero-
type V isolates are resistant to both erythromycin and clin-
damycin and erm(B) and lnu(B) are related to erythromycin
and clindamycin resistance, respectively. Ongoing monitor-
ing for serotype and antibiotic resistance, and research to iden-
tify effective prevention and alternative treatments is an urgent
matter. 
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